Premium
Malignant and benign human mammary disease: Estrogen binding in relation to clinical data
Author(s) -
Terenius L.,
Johansson H.,
Rimsten Å.,
Thorén L.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197405)33:5<1364::aid-cncr2820330522>3.0.co;2-7
Subject(s) - medicine , pathology , estrogen , histology , stage (stratigraphy) , mammary gland , carcinoma , breast cancer , cancer , biology , paleontology
The estrogen binding capacity (EBC) of biopsies from human mammary carcinoma, benign mammary disease, and from “normal” tissue surrounding the tumors was measured. The biopsies were classified following a statistical criterion as positive (having EBC) or negative. Of 105 cases of breast carcinoma, 49% were positive and 51% were negative. Only 5 of 35 cases of benign disease were positive; no positive case of normal tissue was observed. There was no significant correlation between the presence of EBC in a tumor and tumor histology, differentiation, or cellularity, nor between EBC and the menopausal age of the patient or the clinical stage of the disease. On die other hand, the magnitude of the EBC was significantly higher in tumors of medium than of low differentiation and higher with high than with medium cellularity. Ductal carcinomas had higher EBC than adenocarcinomas. In a limited number of cases, EBC values were determined in primary and secondary tumors in the same patient. Provided differences in cellularity were taken into account, the assignment of EBC of the secondary tumor coincided with that of the primary tumor in 6 cases out of 8.